1. Belgium Stocks

  2. •

    Finance

  3. •

    Financial conglomerates
Financiere de Tubize S.A.

Financiere de Tubize S.A.

199.27
EUR
+18.87
(+10.46%)
10.07BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
1
1.36
4.77
4.07
6.42
6.4
6.37
5.85
1.88
1.91
1.98
2.02
2.09
- -
Free Cash Flow per Basic Share
-0.02
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.48
0.48
0.48
0.5
0.52
0.54
0.56
0.62
0.68
0.75
0.86
0.97
1.04
- -
Book Value per Share
33.56
36.36
43.71
43.94
55.31
60.06
59.85
62.74
38.3
39.35
40.36
41.35
42.36
44.62
Tangible Book Value per Share
33.56
36.36
43.71
43.94
55.31
60.06
59.85
62.74
38.3
39.35
40.36
41.35
42.36
44.62
Basic Weighted Avg Shares
45
45
45
45
45
45
45
45
45
45
45
45
45
45
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
-37,266.67
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
44
61
213
181
286
285
284
261
84
85
88
90
93
- -
Effective Tax Rate (%)
3.77
0.19
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
9,456,800
- -
- -
- -
- -
- -
- -
- -
Working Capital
-57
-50
-51
-102
-53
-52
-53
-33
-38
-86
-123
-88
-47
50
LT Debt
167
138
237
141
140
90
34
- -
- -
- -
- -
- -
- -
- -
Total Equity
1,497
1,622
1,947
1,958
2,116
2,340
2,664
2,793
1,705
1,752
1,797
1,840
1,886
1,986
Return on Invested Capital (%)
-0.05
-0.04
- -
- -
- -
-0.04
-0.04
-0.08
-0.07
-0.1
-0.12
-0.12
-0.16
- -
Return on Capital (%)
3.16
3.94
- -
- -
- -
12.01
10.89
9.36
3.73
4.93
4.92
4.93
4.99
- -
Return on Common Equity (%)
3.01
3.9
11.91
9.28
14.04
12.8
11.34
9.55
3.72
4.93
4.97
4.95
5
- -

Capital Structure

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
45
45
45
Market Capitalization
5,911
9,303
10,069

Working Capital

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
4
2
50
Cash, Cash Equivalents & STI
4
1
50
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
49
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.91%
-5.75%
2.45%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-2.27%
-11.37%
3.47%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
8.1%
10.94%
7.27%

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
2.02
2025
- -
- -
2.09
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.97
2025
- -
- -
1.04
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Eric Nys
Full Time Employees
3
Sector
Finance
Industry
Financial conglomerates
Address
Allee de la Recherche 60 Brussels BU Belgium 1070
IPO Date
Jan 2, 1987
Website
financiere-tubize.be
Similar Companies
Strategy Inc (NASDAQ:MSTR)
BitMine Immersion Technologies, Inc. (NYSE:BMNR)
Strive, Inc. (NASDAQ:ASST)
Hyperliquid Strategies Inc (NASDAQ:PURR)
Stablecoin Development Corporation (AMEX:SDEV)
Jio Financial Services Limited (NSE:JIOFIN)
Business
Financière de Tubize S.A. is a Belgian holding company primarily engaged in investment activities, notably holding a 36.27% stake in the listed biopharmaceutical group UCB. The company's core business centers on its equity investment in UCB, which develops and markets treatments for serious illnesses affecting the immune and central nervous systems, including gene therapy and rare disease treatments. Financière de Tubize operates as a mono holding entity providing long-term financial support to UCB, thereby facilitating its sustained research and development efforts and global product launches. Founded in 1928 and headquartered in Brussels, Belgium, Financière de Tubize ensures strategic stability for UCB's growth and innovation initiatives. Recent major developments include the continued acquisition of UCB shares, which has increased Financière de Tubize's stake and enhanced its capacity to support UCB financially if required. In 2024, Financière de Tubize acquired 53,706 UCB shares, leading to a total investment of approximately €210.1 million over recent years and an unrealized capital gain of €259.2 million. The company also reported a profit increase to €90.1 million in 2024 and actively reduced its bank debt from €79.2 million at the end of 2023 to €41.3 million by year-end 2024. Additionally, it proposed a 7% dividend increase for 2024, reflecting strong financial performance linked to UCB's operational success and share price appreciation. These strategic financial moves underscore Financière de Tubize’s role as a key investor and financial backer within the biopharmaceutical industry.